CA2985777A1 - Treatment of beta-thalassemia using actrii ligand traps - Google Patents

Treatment of beta-thalassemia using actrii ligand traps

Info

Publication number
CA2985777A1
CA2985777A1 CA2985777A CA2985777A CA2985777A1 CA 2985777 A1 CA2985777 A1 CA 2985777A1 CA 2985777 A CA2985777 A CA 2985777A CA 2985777 A CA2985777 A CA 2985777A CA 2985777 A1 CA2985777 A1 CA 2985777A1
Authority
CA
Canada
Prior art keywords
subject
beta
signaling inhibitor
actriib
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2985777A
Other languages
English (en)
French (fr)
Inventor
Kenneth M. Attie
Abderrahmane LAADEM
Rajesh Chopra
Jay BACKSTROM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Acceleron Pharma Inc
Original Assignee
Celgene Corp
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Acceleron Pharma Inc filed Critical Celgene Corp
Publication of CA2985777A1 publication Critical patent/CA2985777A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2985777A 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps Pending CA2985777A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19
PCT/US2016/031999 WO2016183280A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Publications (1)

Publication Number Publication Date
CA2985777A1 true CA2985777A1 (en) 2016-11-17

Family

ID=57248528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985777A Pending CA2985777A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Country Status (15)

Country Link
US (1) US20180125928A1 (https=)
EP (1) EP3294320A4 (https=)
JP (2) JP6976859B2 (https=)
KR (1) KR102640198B1 (https=)
CN (1) CN107847562A (https=)
AU (2) AU2016261913B2 (https=)
CA (1) CA2985777A1 (https=)
HK (1) HK1251157A1 (https=)
IL (2) IL284686B2 (https=)
JO (1) JOP20160092B1 (https=)
MY (1) MY189601A (https=)
PH (1) PH12017502079A1 (https=)
TN (1) TN2017000468A1 (https=)
TW (2) TWI814187B (https=)
WO (1) WO2016183280A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MA42160A (fr) 2015-05-20 2018-03-28 Maria Cappellini Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
HRP20210694T1 (hr) 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije
PL3490582T3 (pl) 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
HRP20241477T1 (hr) * 2017-06-14 2025-01-03 Celgene Corporation Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
US20210346464A1 (en) * 2018-10-31 2021-11-11 Celgene Corporation TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS
EP3999059A1 (en) 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021211418A1 (en) * 2020-04-13 2021-10-21 Celgene Corporation Methods for treating anemia using an actriib ligand trap and fedratinib
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
EP4274600A4 (en) * 2021-01-08 2024-11-20 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION
US20250268878A1 (en) 2021-01-20 2025-08-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
EP4731218A1 (en) 2023-06-26 2026-04-29 Vifor (International) AG Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
DK2124999T3 (da) * 2006-12-18 2013-01-14 Acceleron Pharma Inc Activin-actrii antagonister og anvendelser til behandling af anæmi
AU2009262970A1 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
SMT202300222T1 (it) * 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
BR112014009528B1 (pt) * 2011-10-17 2020-12-29 Acceleron Pharma, Inc. usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
EA201491578A1 (ru) * 2012-03-30 2015-04-30 Шир Хьюман Дженетик Терапис, Инк. Подкожное введение идуронат-2-сульфатазы
AU2013334660B2 (en) * 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
CN104968801B (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
SG11201504038XA (en) * 2012-11-27 2015-06-29 Childrens Medical Center Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction

Also Published As

Publication number Publication date
TN2017000468A1 (en) 2019-04-12
CN107847562A (zh) 2018-03-27
EP3294320A4 (en) 2018-12-26
IL284686B2 (en) 2023-05-01
AU2021258087A1 (en) 2021-11-25
TW201709927A (zh) 2017-03-16
TWI814187B (zh) 2023-09-01
IL284686A (en) 2021-08-31
NZ737043A (en) 2025-02-28
PH12017502079A1 (en) 2018-06-11
JOP20160092B1 (ar) 2023-03-28
AU2016261913A1 (en) 2017-11-30
JP6976859B2 (ja) 2021-12-08
AU2016261913B2 (en) 2021-08-12
JP2018520094A (ja) 2018-07-26
US20180125928A1 (en) 2018-05-10
AU2021258087B2 (en) 2023-04-27
WO2016183280A1 (en) 2016-11-17
IL284686B (en) 2023-01-01
HK1251157A1 (zh) 2019-01-25
MY189601A (en) 2022-02-18
IL255527B (en) 2021-07-29
IL255527A (en) 2018-01-31
TW202231294A (zh) 2022-08-16
KR20180006437A (ko) 2018-01-17
KR102640198B1 (ko) 2024-02-23
TWI762444B (zh) 2022-05-01
JP2021191755A (ja) 2021-12-16
EP3294320A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
AU2015358469B2 (en) Activin-ActRII antagonists and uses for treating anemia
EP3308796B1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
EP3638243A1 (en) Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
US20230142386A1 (en) Activin-actrii antagonists and uses for treating anemia
HK1254086B (en) Activin-actrii antagonists and uses for treating bone and other disorders
NZ747422B2 (en) Activin-actrii antagonists and uses for treating bone and other disorders
HK1214525B (en) Activin-actrii antagonists and uses for treating bone and other disorders
HK1245397B (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210510

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250520

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250910

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250911

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401